FDA committee split on Olumiant dosing

FDA's Arthritis Advisory Committee voted on April 23 in favor of approving a once-daily 2 mg dose of rheumatoid arthritis candidate Olumiant

Read the full 222 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE